APA
Click to copy
Ingles, J., Goldstein, J., Thaxton, C., Caleshu, C., Corty, E. W., Crowley, S. B., … Funke, B. (2019). Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. Circulation Genomic and Precision Medicine.
Chicago/Turabian
Click to copy
Ingles, J., J. Goldstein, C. Thaxton, C. Caleshu, Edward W. Corty, Stephanie B. Crowley, Kristen Dougherty, et al. “Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes.” Circulation Genomic and Precision Medicine (2019).
MLA
Click to copy
Ingles, J., et al. “Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes.” Circulation Genomic and Precision Medicine, 2019.
BibTeX Click to copy
@article{j2019a,
title = {Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes},
year = {2019},
journal = {Circulation Genomic and Precision Medicine},
author = {Ingles, J. and Goldstein, J. and Thaxton, C. and Caleshu, C. and Corty, Edward W. and Crowley, Stephanie B. and Dougherty, Kristen and Harrison, S. and McGlaughon, Jennifer L and Milko, L. and Morales, A. and Seifert, Bryce A. and Strande, Natasha T. and Thomson, K. and van Tintelen, J. Peter and Wallace, Kathleen E. and Walsh, R. and Wells, Q. and Whiffin, N. and Witkowski, Leora and Semsarian, C. and Ware, J. and Hershberger, R. and Funke, B.}
}
Background: Genetic testing for families with hypertrophic cardiomyopathy (HCM) provides a significant opportunity to improve care. Recent trends to increase gene panel sizes often mean variants in genes with questionable association are reported to patients. Classification of HCM genes and variants is critical, as misclassification can lead to genetic misdiagnosis. We show the validity of previously reported HCM genes using an established method for evaluating gene-disease associations. Methods: A systematic approach was used to assess the validity of reported gene-disease associations, including associations with isolated HCM and syndromes including left ventricular hypertrophy. Genes were categorized as having definitive, strong, moderate, limited, or no evidence of disease causation. We also reviewed current variant classifications for HCM in ClinVar, a publicly available variant resource. Results: Fifty-seven genes were selected for curation based on their frequent inclusion in HCM testing and prior association reports. Of 33 HCM genes, only 8 (24%) were categorized as definitive (MYBPC3, MYH7, TNNT2, TNNI3, TPM1, ACTC1, MYL2, and MYL3); 3 had moderate evidence (CSRP3, TNNC1, and JPH2; 33%); and 22 (66%) had limited (n=16) or no evidence (n=6). There were 12 of 24 syndromic genes definitively associated with isolated left ventricular hypertrophy. Of 4191 HCM variants in ClinVar, 31% were in genes with limited or no evidence of disease association. Conclusions: The majority of genes previously reported as causative of HCM and commonly included in diagnostic tests have limited or no evidence of disease association. Systematically curated HCM genes are essential to guide appropriate reporting of variants and ensure the best possible outcomes for HCM families.